NCT03174067

Brief Summary

This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal. Primary treatment outcome is attendance at a rapid access addiction medicine clinic within a few days of emergency room presentation. Secondary treatment outcome is treatment status with respect to opioid agonist treatment at one month post emergency room visit.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Mar 2013

Longer than P75 for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

May 24, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 2, 2017

Completed
Last Updated

June 2, 2017

Status Verified

May 1, 2017

Enrollment Period

3.1 years

First QC Date

May 24, 2017

Last Update Submit

May 30, 2017

Conditions

Keywords

buprenorphineemergency department

Outcome Measures

Primary Outcomes (1)

  • Number of participants attending the rapid access clinic

    The number of participants who attend a rapid access clinic assessment after initial enrollment

    2-5 days

Secondary Outcomes (1)

  • Number of participants who are on opioid agonist treatment

    30 days

Study Arms (2)

Buprenorphine

EXPERIMENTAL

Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine

Drug: Buprenorphine

Clonidine

ACTIVE COMPARATOR

Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine

Drug: Clonidine

Interventions

The participant receives buprenorphine

Buprenorphine

The participant receives clonidine

Clonidine

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Presenting to the ED in opioid withdrawal or soon to be in withdrawal
  • Minimum age 16
  • English speaking
  • Active phone number
  • Ontario Health Insurance Program card

You may not qualify if:

  • Pregnant
  • Currently enrolled in a methadone or buprenorphine maintenance
  • Benzodiazepine addiction (or taking \>50mg of valium equivalent/day)
  • Acute hepatitis or liver failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Srivastava A, Kahan M, Njoroge I, Sommer LZ. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Can Fam Physician. 2019 May;65(5):e214-e220.

MeSH Terms

Conditions

Opioid-Related DisordersEmergencies

Interventions

BuprenorphineClonidine

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental DisordersDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-Ring

Study Officials

  • Anita Srivastava, MD

    University of Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff Physician and Associate Professor

Study Record Dates

First Submitted

May 24, 2017

First Posted

June 2, 2017

Study Start

March 1, 2013

Primary Completion

April 1, 2016

Study Completion

November 1, 2016

Last Updated

June 2, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share